Hsa_circ_0005576 promotes osimertinib resistance through the miR‐512‐5p/IGF1R axis in lung adenocarcinoma cells-Reference-Cited by-同舟云学术

Hsa_circ_0005576 promotes osimertinib resistance through the miR‐512‐5p/IGF1R axis in lung adenocarcinoma cells

Published:2021-11-15 Issue:1 Volume:113 Page:79-90
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Liu Suo¹^ORCID,Jiang Zhibin¹,Xiao Peng¹,Li Xiaozhi¹,Chen Yinji¹,Tang Hao¹,Chai Yanfei¹,Liu Yicai¹,Zhu Zhao²,Xie Qianyi³,He Wei⁴,Ma Yuchao¹,Jin Longyu¹^ORCID,Feng Wei¹^ORCID

Affiliation:

1. Department of Cardiothoracic Surgery The Third Xiangya Hospital of Central South University Changsha China

2. Department of Neurosurgery Hunan Cancer HospitalThe Affiliated Cancer Hospital of Xiangya School of MedicineCentral South University Changsha China

3. Department of Radiology The Third Xiangya Hospital of Central South University Changsha China

4. Department of Pediatrics The Third Xiangya Hospital of Central South University Changsha China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15177

Reference37 articles.

1. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

2. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

3. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review